Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of enfortumab vedotin + pembrolizumab versus gemcitabine + platinum in previously untreated advanced or metastatic urothelial cancer
NL-OMON55964Phase 3Recruiting
- Sponsor
- Seagen Inc.
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Enfortumab vedotin + pembrolizumab with Gemcitabine + cisplatin or carboplatin (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jun 2021; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON55964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55964.